Terbinafine vs compound ketoconazole in treating dermatomycosis

AIM: To compare the therapeutic effects of terbinafine and compound ketoconazole in treatment of dermatomycosis. METHODS: Sixty patients (M 41, F19, age 26± s 9 a) with dermatomycosis were randomly divided into 2 groups. Thirty patients were treated with terbinafine, bid for 2 wk. Thirty patients were treated with compound ketoconazole bid for 2 wk. The drug effects were evaluated after the treatment. RESULTS: The total effective rates at the end of treatment were 73 % (22/30) for terbinafine group and 57 %(17/30) for compound ketoconazole group ( P 0.05); and 97 % (29/30) for terbinafine group and 47 % (14/30) for compound ketoconazole group ( P 0.05) at 4 wk. Mycological clearance rates at 2 weeks were 83 % for terbinafine group and 53 % for compound ketoconazole group ( P 0.05); and 97 % for terbinafine group and 37 % for compound ketoconazole group ( P 0.01) at 4 weeks. There were no adverse reactions in both treatment groups. CONCLUSION: Terbinafine is better than compound ketoconazole in the treatment of dermatomycosis.